Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3319 patients) or placebo (3313 patients) [correction] in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS: During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001). CONCLUSIONS: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized controlled trial data regarding in-hospital initiation of MRA therapy among patients with HFrEF is limited to the EPHESUS trial.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [38]
In the citing paper
“Mineralocorticoid receptor antagonists (spironolactone, eplerenone) can also be effective antihypertensive agents (particularly for those with borderline or low potassium levels)89 and are important for morbidity and mortality reduction in patients with left ventricular dysfunction.90,91”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [90]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationDickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Aldosterone-Induced Inflammation in the Rat Heart
Sun, Y., Zhang, J., Lu, L., Chen, S. S., Quinn, M. T., & Weber, K. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64454-9 · Cited by 567
Farquharson, C. A. J., & Struthers, A. D. (2000) · Circulation · doi:10.1161/01.cir.101.6.594 · Cited by 532
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364
Self-citation
Research works printed but not linked: 3
- Rodriguez JA, 1997, Rev Med Chile, 125, 643
- Schaefer A, 2002, Eur Heart J, 23, 401
- de Gasparo M, 1987, J Pharmacol Exp Ther, 240, 650
Cited by
Items 401–500 of 1,018
Cardiac Fibrosis and Arrhythmogenesis
Nguyen, M., Kiriazis, H., Gao, X., & Du, X. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160046 · Cited by 169
Hu, X., Dietz, J. D., Xia, C., Knight, D. R., Loging, W. T., Smith, A. H., Yuan, H., Perry, D. A., & Keiser, J. (2009) · Endocrinology · doi:10.1210/en.2008-1512 · Cited by 150
Lother, A., Berger, S., Gilsbach, R., Rösner, S., Ecke, A., Barreto, F., Bauersachs, J. K., Schütz, G., & Hein, L. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.163287 · Cited by 152
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G. L., Brown, A. S., Ferdinand, K. C., Forciea, M. A., Frishman, W. H., Jaigobin, C. S., et al. (2011) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2011.06.001 · Cited by 172
DeMarco, V. G., Habibi, J., Jia, G., Aroor, A. R., Ramirez‐Perez, F. I., Martinez‐Lemus, L. A., Bender, S. B., Garro, M., Hayden, M. R., Sun, Z., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05674 · Cited by 154
Owens, C. D., Gasper, W. J., Rahman, A. S., & Conte, M. S. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.08.019 · Cited by 144
Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure
Rosenberg, M., Zugck, C., Nelles, M., Juenger, C., Frank, D., Remppis, A., Giannitsis, E., Katus, H. A., & Frey, N. (2008) · Circulation Heart Failure · doi:10.1161/circheartfailure.107.746172 · Cited by 151
Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction
Frazier‐Mills, C. G., Alexander, K. P., Newby, L. K., Anderson, S., Iverson, E. R., Packer, M., Cohn, J. N., Goldstein, S., & Douglas, P. S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.11.041 · Cited by 167
Rude, M. K., Duhaney, T.-A. S., Kuster, G. M., Judge, S., Heo, J., Colucci, W. S., Siwik, D. A., & Sam, F. (2005) · Hypertension · doi:10.1161/01.hyp.0000176236.55322.18 · Cited by 148
50th Anniversary of Aldosterone
Williams, J. S., & Williams, G. H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030490 · Cited by 153
Reconsidering the Roles of the Mineralocorticoid Receptor
Funder, J. W. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.119966 · Cited by 159
Hypertension in Obesity and the Impact of Weight Loss
Cohen, J. B. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0912-4 · Cited by 147
Novel RAAS agonists and antagonists: clinical applications and controversies
Romero, C. A., Orias, M., & Weir, M. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.6 · Cited by 147
Makki, N. M., Brennan, T. M. H., & Girotra, S. R. (2013) · Journal of Intensive Care Medicine · doi:10.1177/0885066613503294 · Cited by 150
2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 149
Velazquez, E. J., Francis, G. S., Armstrong, P. W., Aylward, P. E., Diaz, R., O'Connor, C. M., White, H. D., Henis, M., Rittenhouse, L. M., Kilaru, R., et al. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.08.006 · Cited by 165
Acute Heart Failure Syndromes in Patients With Coronary Artery Disease
Flaherty, J. D., Bax, J. J., Luca, L. D., Rossi, J. S., Davidson, C. J., Filippatos, G. S., Liu, P. P., Konstam, M. A., Greenberg, B., Mehra, M. R., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.072 · Cited by 147
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145
The Role of Coronary Artery Disease in Heart Failure
Lala, A., & Desai, A. S. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.10.002 · Cited by 168
Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach
O’Keefe, J. H., Carter, M. D., & Lavie, C. J. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.8.741 · Cited by 173
Therapeutic Targets in Heart Failure
Schelbert, E. B., Fonarow, G. C., Bonow, R. O., Butler, J., & Gheorghiade, M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.068 · Cited by 145
Mejia-Vilet, J. M., Ramírez, V., Cruz, C., Uribe, N., Gamba, G., & Bobadilla, N. A. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00077.2007 · Cited by 152
Pellman, J., Lyon, R. C., & Sheikh, F. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.09.001 · Cited by 156
Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease
Bertocchio, J., Warnock, D. G., & Jaisser, F. (2011) · Kidney International · doi:10.1038/ki.2011.48 · Cited by 151
Hernandez, A. F., Mi, X., Hammill, B. G., Hammill, S. C., Heidenreich, P. A., Masoudi, F. A., Qualls, L. G., Peterson, E. D., Fonarow, G. C., & Curtis, L. H. (2012) · JAMA · doi:10.1001/jama.2012.14795 · Cited by 147
Rickard, A. J., Morgan, J., Chrissobolis, S., Miller, A. A., Sobey, C. G., & Young, M. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01803 · Cited by 143
Kotecha, D., Manzano, L., Krum, H., Rosano, G., Holmes, J., Altman, D. G., Collins, P. D., Packer, M., Wikstrand, J., Coats, A. J. S., et al. (2016) · BMJ · doi:10.1136/bmj.i1855 · Cited by 139
Management of Low Blood Pressure in Ambulatory Heart Failure with Reduced Ejection Fraction Patients
Cautela, J., Tartière, J., Solal, A. C., Bellemain-Appaix, A., Théron, A., Tibi, T., Januzzi, J. L., Roubille, F., & Girerd, N. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1835 · Cited by 156
Fruhwald, F. M., Fahrleitner-Pammer, A., Berger, R., Leyva, F., Freemantle, N., Erdmann, E., Gras, D., Kappenberger, L., Tavazzi, L., Daubert, J.-C., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl505 · Cited by 141
Aldosterone, mineralocorticoid receptor, and heart failure
Messaoudi, S., Azibani, F., Delcayre, C., & Jaisser, F. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.038 · Cited by 141
South African hypertension guideline 2006.
Seedat, Y. K., Ma, C., Milne, F. J., Opie, L. H., Vj, P.-A., Rayner, B. L., & Veriava, Y. (2006) · PubMed · Cited by 162
Central serous chorioretinopathy: An evidence-based treatment guideline
Feenstra, H. M. A., van Dijk, E. H. C., Cheung, C. M. G., Ohno‐Matsui, K., Lai, T. Y. Y., Koizumi, H., Larsen, M., Querques, G., Downes, S. M., Yzer, S., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101236 · Cited by 154
Hitomi, H., Kiyomoto, H., Nishiyama, A., Hara, T., Moriwaki, K., Kaifu, K., Ihara, G., Fujita, Y., Ugawa, T., & Kohno, M. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.093955 · Cited by 140
Early Aldosterone Blockade in Acute Myocardial Infarction
Beygui, F., Cayla, G., Roule, V., Roubille, F., Delarche, N., Silvain, J., BELLE, E. V., Belle, L., Galinier, M., Motreff, P., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.033 · Cited by 150
Self-citationArai, K., Homma, T., Morikawa, Y., Ubukata, N., Tsuruoka, H., Aoki, K., Ishikawa, H., Mizuno, M., & Sada, T. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.06.015 · Cited by 140
Macdonald, J. E., Kennedy, N., & Struthers, A. D. (2004) · Heart · doi:10.1136/hrt.2003.017368 · Cited by 141
Human Endothelium: Target for Aldosterone
Oberleithner, H., Ludwig, T. E., Riethmüller, C., Hillebrand, U., Albermann, L., Schäfer, C., Shahin, V., & Schillers, H. (2004) · Hypertension · doi:10.1161/01.hyp.0000123572.45556.a5 · Cited by 139
Priori, S. G., Blomström‐Lundqvist, C., Mazzanti, A., Blom, N. A., Borggrefe, M., Camm, A. J., Elliot, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., et al. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.01.001 · Cited by 160
Self-citationMineralocorticoid Receptor and Cardiovascular Disease
Buonafine, M., Bonnard, B., & Jaisser, F. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy120 · Cited by 133
Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension
Frey, F. J., Odermatt, A., & Frey, B. M. (2004) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000133976.32559.b0 · Cited by 137
Suzuki, S., Yoshimura, M., Nakayama, M., Mizuno, Y., Harada, E., Ito, T., Nakamura, S., Abe, K., Yamamuro, M., Sakamoto, T., et al. (2004) · Circulation · doi:10.1161/01.cir.0000141295.60857.30 · Cited by 141
The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation
Lavall, D., Selzer, C., Schuster, P., Lenski, M., Adam, O., Schäfers, H.-J., Böhm, M., & Laufs, U. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.519256 · Cited by 133
Low-dose spironolactone in the management of resistant hypertension: a surveillance study
Lane, D. A., Shah, S., & Beevers, D. G. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e328014954d · Cited by 137
Dual Role for Glucocorticoids in Cardiomyocyte Hypertrophy and Apoptosis
Ren, R., Oakley, R. H., Cruz-Topete, D., & Cidlowski, J. A. (2012) · Endocrinology · doi:10.1210/en.2012-1563 · Cited by 133
Pruthi, D., McCurley, A., Aronovitz, M. A., Galayda, C., Karumanchi, S. A., & Jaffe, I. Z. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302854 · Cited by 137
Gayat, E., Arrigo, M., Littnerova, S., Sato, N., Parenica, J., Ishihara, S., Spinar, J., Müller, C., Harjola, V.-P., Lassus, J., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.932 · Cited by 133
Bozkurt, B., & Khalaf, S. Z. (2017) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-13-4-216 · Cited by 157
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.10.009 · Cited by 148
Quinkler, M., Zehnder, D., Eardley, K. S., Lepenies, J., Howie, A. J., Hughes, S. V., Cockwell, P., Hewison, M., & Stewart, P. M. (2005) · Circulation · doi:10.1161/circulationaha.105.539122 · Cited by 130
Aldosterone in Chronic Kidney and Cardiac Disease
Hostetter, T. H., & Ibrahim, H. N. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000086472.65806.73 · Cited by 137
Novel therapeutic approaches to post-infarction remodelling
Fraccarollo, D., Galuppo, P., & Bauersachs, J. K. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs109 · Cited by 150
Solomon, S. D., Hee Shin, S., Shah, A., Skali, H., Desai, A., Kober, L., Maggioni, A. P., Rouleau, J. L., Kelly, R. Y., Hester, A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq522 · Cited by 138
Management of Ventricular Arrhythmias in Patients With Advanced Heart Failure
Santangeli, P., Rame, J. E., Birati, E. Y., & Marchlinski, F. E. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.047 · Cited by 145
Aldosterone as a cardiovascular risk factor
Rossi, G. P., Boscaro, M., Ronconi, V., & Funder, J. W. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.02.010 · Cited by 148
ANDERSON, M. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.002 · Cited by 144
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism
Karagiannis, A., Tziomalos, K., Papageorgiou, A., Kakafika, A. I., Pagourelias, E. D., Anagnostis, P., Athyros, V. G., & Mikhailidis, D. P. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.4.509 · Cited by 133
Shah, K. B., Rao, K., Sawyer, R., & Gottlieb, S. S. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.010 · Cited by 143
Origin of Aldosterone in the Rat Heart
Gomez-Sanchez, E. P., Ahmad, N., Romero, D. G., & Gomez-Sanchez, C. E. (2004) · Endocrinology · doi:10.1210/en.2004-0295 · Cited by 135
Udelson, J. E., Feldman, A. M., Greenberg, B., Pitt, B., Mukherjee, R., Solomon, H. A., & Konstam, M. A. (2010) · Circulation Heart Failure · doi:10.1161/circheartfailure.109.906909 · Cited by 145
Self-citationGöhler, A., Geisler, B. P., Manne‐Goehler, J., Kosiborod, M., Zhang, Z., Weintraub, W. S., Spertus, J. A., Gazelle, G. S., Siebert, U., & Cohen, D. J. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00425.x · Cited by 136
Treatment of Hypertension in Patients With Coronary Artery Disease
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.038 · Cited by 155
Torabi, A., Cleland, J. G. F., Khan, N. K., Loh, P. H., Clark, A. L., Alamgir, F., Caplin, J., Rigby, A. S., & Goode, K. M. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn096 · Cited by 135
Structural remodeling in atrial fibrillation
Corradi, D., Callegari, S., Maestri, R., Benussi, S., & Alfieri, O. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1370 · Cited by 150
Shibata, H., & Itoh, H. (2012) · American Journal of Hypertension · doi:10.1038/ajh.2011.245 · Cited by 140
Aldosterone Induces Superoxide Generation via Rac1 Activation in Endothelial Cells
Iwashima, F., Yoshimoto, T., Minami, I., Sakurada, M., Hirono, Y., & Hirata, Y. (2007) · Endocrinology · doi:10.1210/en.2007-0864 · Cited by 144
Fraccarollo, D., Galuppo, P., Schraut, S., Kneitz, S., van Rooijen, N., Ertl, G., & Bauersachs, J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.100941 · Cited by 133
Distinguishing the Antihypertensive and Electrolyte Effects of Eplerenone
Levy, D. G., Rocha, R., & Funder, J. W. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032149 · Cited by 133
Cubbon, R. M., Gale, C. P., Kearney, L. C., Schechter, C. B., Brooksby, W. P., Nolan, J., Fox, K. A. A., Rajwani, A., Baig, W., Groves, D., et al. (2011) · Circulation: Heart Failure · doi:10.1161/circheartfailure.110.959882 · Cited by 131
Bianchi, S., Aucella, F., Nicola, L. D., Genovesi, S., Paoletti, E., & Regolisti, G. (2019) · Journal of Nephrology · doi:10.1007/s40620-019-00617-y · Cited by 145
Sato, A., Hayashi, K., & Saruta, T. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.06.029 · Cited by 132
New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone
Bobadilla, N. A., & Gamba, G. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00072.2007 · Cited by 132
Boerrigter, G., Soergel, D. G., Violin, J. D., Lark, M. W., & Burnett, J. C. J. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.969220 · Cited by 130
Kelly, D., Squire, I. B., Khan, S. Q., Quinn, P. A., Struck, J., Morgenthaler, N. G., Davies, J. E., & Ng, L. L. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.07.231 · Cited by 141
Chronic Heart Failure: Current Evidence, Challenges to Therapy, and Future Directions
Morrissey, R. P., Czer, L. S. C., & Shah, P. K. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11592090-000000000-00000 · Cited by 137
Yamaji, M., Tsutamoto, T., Kawahara, C., Nishiyama, K., Yamamoto, T., Fujii, M., & Horie, M. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.04.024 · Cited by 137
Rumsfeld, J. S., Jones, P. G., Whooley, M. A., Sullivan, M. D., Pitt, B., Weintraub, W. S., & Spertus, J. A. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.036 · Cited by 140
Self-citationKey Issues in End Point Selection for Heart Failure Trials: Composite End Points
Neaton, J. D., Gray, G. W., Zuckerman, B. D., & Konstam, M. A. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.08.350 · Cited by 138
Self-citationBienvenu, L. A., Morgan, J., Rickard, A. J., Tesch, G. H., Cranston, G. A., Fletcher, E. K., Delbridge, L. M. D., & Young, M. J. (2012) · Endocrinology · doi:10.1210/en.2011-2098 · Cited by 128
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., & Stevenson, W. G. (2006) · Circulation · doi:10.1161/circulationaha.106.655761 · Cited by 158
McMurray, J., Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, F. D. R., Krum, H., Maggioni, A., McKelvie, R. S., Piña, I. L., et al. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.07.002 · Cited by 131
Mineralocorticoid Receptor Activation Promotes Vascular Cell Calcification
Jaffe, I. Z., Tintut, Y., Newfell, B. G., Demer, L. L., & Mendelsohn, M. E. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000258414.59393.89 · Cited by 131
Klein, L., O’Connor, C. M., Gattis, W. A., Zampino, M., Luca, L. D., Vitarelli, A., Fedele, F., & Gheorghiade, M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03336-2 · Cited by 151
New aspects of rapid aldosterone signaling
Großmann, C., & Gekle, M. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.02.005 · Cited by 147
Key inflammatory mechanisms underlying heart failure
Riehle, C., & Bauersachs, J. K. (2019) · Herz · doi:10.1007/s00059-019-4785-8 · Cited by 138
Diagnosis and management of primary aldosteronism: An updated review
Chao, C.-T., Wu, V.-C., Kuo, C.-C., Lin, Y.-H., Chang, C.-C., Chueh, S. J., Wu, K.-D., Pimenta, E., & Stowasser, M. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.785234 · Cited by 129
Calhoun, D. A., & White, W. B. (2008) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2008.05.005 · Cited by 128
Ivanés, F., Susen, S., Mouquet, F., Pigny, P., Cuilleret, F., Sautière, K., Collet, J., Beygui, F., Hennache, B., Ennezat, P. V., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr176 · Cited by 128
Rossignol, P., Ménard, J., Fay, R., Gustafsson, F., Pitt, B., & Zannad, F. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.04.049 · Cited by 128
Self-citationKim, H. W., Klem, I., Shah, D. J., Wu, E., Meyers, S. N., Parker, M. A., Crowley, A. L., Bonow, R. O., Judd, R. M., & Kim, R. J. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000057 · Cited by 129
The Clinical Implications of Aldosterone Escape in Congestive Heart Failure
Struthers, A. D. (2004) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2004.04.013 · Cited by 135
Aldosteronism and Peripheral Blood Mononuclear Cell Activation: A Neuroendocrine-Immune Interface
Ahokas, R. A., Warrington, K. J., Gerling, I., Sun, Y., Wodi, L. A., Herring, P. A., Lu, L., Bhattacharya, S. K., Postlethwaite, A. E., & Weber, K. T. (2003) · Circulation Research · doi:10.1161/01.res.0000102404.81461.25 · Cited by 133
Cardioprotective function of cardiac macrophages
Fujiu, K., Wang, J., & Nagai, R. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu059 · Cited by 127
Khatib, R., Joseph, P., Briel, M., Yusuf, S., & Healey, J. S. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.02.009 · Cited by 130
Davies, J. I., Band, M. M., Morris, A. D., & Struthers, A. D. (2004) · Diabetologia · doi:10.1007/s00125-004-1510-8 · Cited by 131
Clark, H., Krum, H., & Hopper, I. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.13 · Cited by 122
Garnier, A., Bendall, J. K., Fuchs, S., Escoubet, B., Rochais, F., Hoerter, J. A., Nehmé, J., Ambroisine, M.-L., Angelis, N. D., Morineau, G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000142858.44680.27 · Cited by 125
S3-Leitlinie „Aszites, spontan bakterielle Peritonitis, hepatorenales Syndrom”
Gerbes, A. L., Gülberg, V., Sauerbruch, T., Wiest, R., Appenrodt, B., Bahr, M., Dollinger, M., Rossle, M. P., & Schepke, M. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0031-1273405 · Cited by 141
Galmiche, G., Pizard, A., Gueret, A., El Moghrabi, S., Ouvrard-Pascaud, A., Berger, S., Challande, P., Jaffe, I. Z., Labat, C., Lacolley, P., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01967 · Cited by 117
Essential role of ICAM-1 in aldosterone-induced atherosclerosis
Marzolla, V., Armani, A., Mammi, C., Moss, M. E., Pagliarini, V., Pontecorvo, L., Antelmi, A., Fabbri, A., Rosano, G. M. C., Jaffe, I. Z., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.01.013 · Cited by 127
Head-to-head comparison of clustering methods for heterogeneous data: a simulation-driven benchmark
Preud’homme, G., Duarte, K., Dalleau, K., Lacomblez, C., Bresso, E., Smaïl‐Tabbone, M., Couceiro, M., Devignes, M., Kobayashi, M., Huttin, O., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83340-8 · Cited by 125
Self-citation
Metadata
- Authors
- Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M.
- Affiliations
- University of Michigan (US)
- Cardiovascular Research Foundation (US)
- University of Minnesota (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1309-1321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152094259
- Cited by
- 4,941
- References
- 27
- Citations by year
- 2026: 120 · 2025: 148 · 2024: 136 · 2023: 150 · 2022: 155 · 2021: 156 · 2020: 164 · 2019: 147 · 2018: 187 · 2017: 188 · 2016: 177 · 2015: 224 · 2014: 239 · 2013: 270 · 2012: 281
- FWCI
- 180.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, left ventricular dysfunction, myocardial infarction, heart failure, cardiovascular mortality, sudden cardiac death, hyperkalemia, hypokalemia, hospitalization, ventricular arrhythmias, mortality reduction, secondary prevention
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Blood Pressure, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Myocardial Infarction, Potassium, Spironolactone, Survival Analysis, Death, Sudden, Cardiac, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.